Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
PMV Pharmaceuticals, Inc
Tizona Therapeutics, Inc
Essen Biotech
IDEAYA Biosciences
University of Kentucky
University of California, San Francisco
Maastricht University Medical Center
Evopoint Biosciences Inc.
Portland VA Medical Center